Bastian Schilling

Associate Professor

Universitätsklinikum Würzburg

Germany

Research Interests

Explore related searches

Professors in Germany Professors in Cancer Biology Cancer Biology professors in Germany

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (10)

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Collaborators (8)

Jonas Wohlfarth

University Hospital Würzburg

GERMANY

View details

Kilian Wistuba-Hamprecht

University Hospital Tübingen

GERMANY

View details

Benoit Blanchet

FRANCE

View details

Markus V Heppt

Universitätsklinikum Erlangen

GERMANY

View details

Ramon Staeger

University Hospital of Zurich

SWITZERLAND

View details

Julia Huynh

Charité - Universitätsmedizin Berlin

GERMANY

View details

Elisabeth Livingstone

University Hospital Essen

GERMANY

View details

Olga Isaeva

Antoni van Leeuwenhoek Nederlands Kanker Instituut

NETHERLANDS

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Bastian Schilling

Research Interests

Explore related searches

Contact this professor

Articles (10)

Adjuvant treatment and outcome of stage III melanoma patients: Results of a multicenter real-world DeCOG study

Tebentafusp in Patients with Metastatic Uveal Melanoma: A Real-Life Retrospective Multicenter Study

Predicting Microenvironment in CXCR4- and FAP-Positive Solid Tumors—A Pan-Cancer Machine Learning Workflow for Theranostic Target Structures

Monitoring of Dabrafenib and Trametinib in Serum and Self-Sampled Capillary Blood in Patients with BRAFV600-Mutant Melanoma

How representative are data from global trials on programmed death-1 blockade in melanoma?

PRAME Expression as Helpful Immunohistochemical Marker in Rhabdoid Melanoma

Blood Eosinophils Are Associated with Efficacy of Targeted Therapy in Patients with Advanced Melanoma

Differential effects of PD-1 and CTLA-4 blockade on the melanoma-reactive CD8 T cell response

Activity of ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma

Factors Influencing the Adjuvant Therapy Decision: Results of a Real-World Multicenter Data Analysis of 904 Melanoma Patients

Collaborators (8)

Jonas Wohlfarth

Kilian Wistuba-Hamprecht

Benoit Blanchet

Markus V Heppt

Ramon Staeger

Julia Huynh

Elisabeth Livingstone

Olga Isaeva

Make your next move.